Generali Asset Management SPA SGR Invests $952,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Generali Asset Management SPA SGR acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,733 shares of the specialty pharmaceutical company's stock, valued at approximately $952,000.

Several other institutional investors also recently bought and sold shares of the company. Corient Private Wealth LLC boosted its holdings in Jazz Pharmaceuticals by 34.5% in the fourth quarter. Corient Private Wealth LLC now owns 10,857 shares of the specialty pharmaceutical company's stock worth $1,335,000 after acquiring an additional 2,784 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Jazz Pharmaceuticals by 19.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,146 shares of the specialty pharmaceutical company's stock valued at $387,000 after acquiring an additional 502 shares in the last quarter. Globeflex Capital L P raised its position in shares of Jazz Pharmaceuticals by 59.1% in the 4th quarter. Globeflex Capital L P now owns 8,073 shares of the specialty pharmaceutical company's stock valued at $994,000 after purchasing an additional 3,000 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Jazz Pharmaceuticals by 501.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company's stock worth $13,800,000 after purchasing an additional 93,422 shares in the last quarter. Finally, Avantax Advisory Services Inc. purchased a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $264,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CMO Robert Iannone sold 2,403 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $138.41, for a total transaction of $332,599.23. Following the completion of the sale, the chief marketing officer now directly owns 79,621 shares of the company's stock, valued at approximately $11,020,342.61. The trade was a 2.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,022,825 in the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on JAZZ shares. Truist Financial raised their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their target price for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Morgan Stanley reiterated an "overweight" rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $6.77 during midday trading on Tuesday, hitting $135.25. 1,534,183 shares of the stock traded hands, compared to its average volume of 704,698. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock's fifty day simple moving average is $131.79 and its 200-day simple moving average is $122.03. The firm has a market cap of $8.21 billion, a P/E ratio of 19.05, a PEG ratio of 1.04 and a beta of 0.44.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.